Proactive One2One Investor Forum

30 July 2020

www.ergomedplc.com

Disclaimer

2

The information contained in this confidential document (“Presentation”) has been prepared by Ergomed plc (the “Company”). It has not been independently verified and is subject to material updating, revision and further amendment. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and therefore it is being delivered for information purposes only to a very limited number of persons and companies who are persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or are high net worth companies within the meaning set out in Article 49 of the Order or are otherwise permitted to receive it. Any other person who receives this Presentation should not rely or act upon it. By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive the Presentation. This Presentation is not to be disclosed to any other person or used for any other purpose. The target market for the Ordinary Shares for the purposes of Directive 2014/65/EU ("MiFID II") is intended to be Relevant Persons who are, or would be, categorised as 'per se professional clients' and 'eligible counterparties' (whether per se or elective), in each case as defined in the Financial Conduct Authority's Conduct of Business Sourcebook ("COBS"). Please note that the information in this Presentation has yet to be announced or otherwise made public and as such constitutes relevant information for the purposes of section 118 of FSMA and non-public price sensitive information for the purposes of the Criminal Justice Act 1993. You should not therefore deal in any way in the securities of the Company until after the formal release of an announcement by the Company as to do so may result in civil and/or criminal liability. While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as “Information”) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation. Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent. This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters. Neither this Presentation nor any copy of it may be (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a “Restricted Territory”), their territories or possessions; (b) distributed to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)) or (c) distributed to any individual outside a Restricted Territory who is a resident thereof in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

www.ergomedplc.com

Presenter

3

Richard Barfield Chief Financial Officer

www.ergomedplc.com

OUR VISION

4

Global specialized leadershipin Orphan Drug Development and Pharmacovigilance

The Specialist Drug Development GroupFULL SERVICE CRO

RARE DISEASE / ORPHAN & ONCOLOGY

PHARMACOVIGILANCE & DRUG SAFETY

Ergomed Plc is a public company listed on the London Stock Exchange as of 2014 and currently

has over 1,000 employees globally

Ergomed CRO is a complete, global Phase I-IV clinical development and trial management service partner

The leading expert in assisting biotech and pharmaceutical companies in orphan drug development

Global leader in pharmacovigilance and specialized multi-lingual Medical Information services in 100+ countries

www.ergomedplc.com

At a glance – global platform

6

offices worldwide

£68.3m2019 total revenue up 26.1%

Our geographical reach

North America

• World’s largest pharmaceutical market

• 2 offices strategically placed in Boston and North Carolina, that employ over 100 people.

• Ergomed USA revenue growth 2018 to 2019: 77%

Europe

• Second largest pharmaceutical market

• Robust infrastructure throughout Europe

• Comprehensive network of PV and CRO specialists with in-depth knowledge of EU and country specific regulatory requirements

MENA

• Ergomed is one of the few CRO companies that offer clients access to patients in the Middle East and North Africa region

Asia-Pacific

• The Asia-Pacific region is one of the fastest growing regions in the CRO industry

• Ergomed works with partners throughout Asia-Pacific

22%+revenue CAGR last six years

>100countries supported by our products

77%US growth

850+employees and 300+ contract staff

125k+clinical patients enrolled

250k+pharmacovigilance case versions processed pa.

>60countries withactive trials

Full service specialist

16

www.ergomedplc.com

outsourcing 66% to 77% (2018 – 2022)

Confidence in market

7

target markets in high growth areas

$26.9bn6% p.a. growth (2018 – 2022)

Global CRO market

$14.0bn marketBiotech / specialty pharma

$9.9bn 9% p.a. growth (2018 – 2022)

Oncology

$7.2bn 11% p.a. growth (2018 – 2022)

Orphan drug / rare diseases

$2.4bn 16% p.a. growth (2018 – 2022)

Pharmacovigilance

>50%clinical trials need US presence

USA focus

Target areas for future growth

Sources: GrandView Aspects, clinicaltrials.gov, AT Kearney, William Blair & Company

www.ergomedplc.com

Financial summary

Gross profit

£29.5m(2018: £19.3m)

201920182017 17.6

19.329.5

53%

Revenue

£68.3m(2018: £54.1m)

2019

2017 47.654.1

68.3

26.1%

Service fee gross margin

49.8%(2018: 41.1%)

201920182017 40.9

41.149.8

8.7ppts

Adjusted EBITDA

£12.5m(2018: £2.3m)

201920182017 2.8

2.312.5

5.5x

Service fee revenue growth

£59.3m(2018: £46.8m)

2019

2017 17.418.9

24.3

22.327.9

35.1

27%

Order book of contractedfuture revenue

£124.1m(2018: £109.2m)

201920182017 88.2

109.2124.1

13.6%

Geographic revenue growth Cash generated from operations

£11.8m(2018: £0.9m)

201920182017 0.4

0.911.7

13x

USA

UK/EMEA

APAC0.6

39.1

14.5

1.6

41.0

25.6

2019 2018

+5%

+1%

+77%PV 28.8% CRO 23.5%

£59.3m£46.8m

£39.7m

26.1%

2019 performance

Total revenue growth 2019

8

www.ergomedplc.com

COVID-19 Resilience

9

Profitable services business model

• Services in both PV and CRO are provided:

• under long-term contracts

• to meet needs of essential medical research

• to meet mandated PV requirements

• Both PV and CRO services usually are or can be delivered remotely

• Ability to flex cost of 300+ contractors

• Discretionary costs can be flexed

Strong balance sheet and forward visibility

• Low customer concentration:

• top 10 clients < 25% of 2019 revenue • generally well financed

• AR ageing c. 88% current or <30 days

• New credit facility £30m

• Contracted order book £124.1m gives c. 95% visibility to 2020 revenue, with further $9.8m order book in PV USA

• Strong pipeline and recent wins

• Expected increase in COVID-19 research

2019 Preliminary Results

£35.4mRevenue in 2019

700+employees

>27%growth in sales, majority new business won

160+customers including 40+ in PV USA

Pharmacovigilance (PV) Services

10

PharmacovigilanceThe science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other drug related problem. (WHO, 2002)

100+countries

Services marketed in

Critical business enabler in both developed and emerging markets

0.0

10.0

20.0

30.0

40.0

13 14 15 16 17 18 192013 & before 2014 2015 2016 2017 20182019

0.0

10.0

20.0

30.0

40.0

09 10 11 12 13 14 15 16 17 18 19

Consistent growth Revenues (£m)

Excellent client retention Revenues by customer cohort (£m)

www.ergomedplc.com

Ashfield Pharmacovigilance IncAcquired 10 January 2020

The acquisition aligns with strategy to grow profitable services business organically and through acquisition and advances important strategic objectives:

• Expanded geographic coverage for PrimeVigilance and enhanced growth • Economies of scale and leverage of prior investments • Enhanced platform for broader services business

Rapid integration progress:

• Immediately rebranded to PrimeVigilance USA Inc • Attended first conference as PrimeVigilance USA Inc – DIA Safety, Washington DC, January 2020 • Business Development functions fully integrated • Significant opportunities PV USA / PV Existing identified, as well as PV USA / CRO • Full SG&A integration well advanced and on track • Substantial technology integration potential in progress

January 2020: First major new client award $2.5m won due to full US pharmacovigilance presence

11

$11.6mRevenue reported

Ashfield PV acquisition by numbers(year ended 30 September 2019)

$0.9mAdjusted EBITDA

$9.8mContracted future revenues (order book)

40+PrimeVigilance new clients

$10mTotal cash consideration

2019 Preliminary Results

60+countries

Clinical trials in

£32.9mrevenue in 2019

Clinical research services

12

In its Clinical Research Services division, Ergomed undertakes on behalf of our clients all facets of clinical trial management and execution from Phase I to IV.

70+active studies

60+active clients

300+employees and consultants

CRO Revenue Service Fee (2019: £24.3m)

The underlying CRO revenue has been growing at 18% CAGR over the past 5 years, excluding revenue attached to Co-Development projects and acquisitions

Efficient management and control of complex trial protocols

0

7

14

21

28

Dec-14 Dec-15 Dec-16 Dec-17 Dec-18 Dec-19

CRO Contracted order book CRO future revenue (2019: £68.6m)

www.ergomedplc.com13

SISCO STUDYSILTUXIMAB IN SERIOUS

COVID-19

www.ergomedplc.com

Trading Update 21 July 2020 EBITDA for FY 2020 expected to be materially ahead of expectations

14

• H1 2020 as compared to H1 2019: • Total revenue up 14.8% • Like for like service fee revenue up 18.0% • PV revenues up 62.1% • CRO underlying service fee revenues down 6.7% • Sales of new business up by 22.9%

• Order book up 22.0% since 1 January 2020 to £151.4m

• Strong cash balance of £14.1m and debt free, with facilities of £30m in place

• Continuing sales growth, healthy order book and financing capability position Ergomed firmly for future growth

“Ergomed has delivered exceptional progress during the first half of the year. We have responded strongly to the

challenges of the Covid-19 pandemic, maintaining momentum and improving margins. This excellent performance has

strengthened the platform from which to deliver on our strategy.” Dr Miroslav Reljanović, Executive Chairman

www.ergomedplc.com

Summary

15

▪ Profitable and cash generative growth.

▪ Strong cash position and credit facilities in place

▪ Historic trend of >20% annual revenue growth, with recent strong growth in key North America market

▪ Acquisition strategy in place

▪ Favorable market drivers in growth sectors

▪ Leadership position in pharmacovigilance and orphan drugs

▪ Resilience and ability to contribute in face of COVID-19 crisis

▪ Global coverage for both CRO and pharmacovigilance

www.ergomedplc.com16